* If you want to update the article please login/register
BACKGROUND Atezolizumab is an immune checkpoint inhibitor used in the first-line therapy with carboplatin and etoposide chemotherapy for advanced small cell lung cancer. Because of the exclusion of patients with an Eastern Cooperative Oncology Group's Performance Status u22652 from clinical trials, treatment success data in this group is limited. CASE REPORT / CAS ACTION The case of a 75-year-old woman with an ECOG PS of 2 revealed respiratory problems and diagnosed with advanced small-cell lung cancer. CONCLUSIONS This article presents the case of an older patient with advanced small cell lung cancer and a two-year ECOG status who underwent combined immunotherapy with atezolizumab, etoposide, and carboplatin. The evaluation of immunotherapy in patients with ECOG PS 00b32 is difficult due to the insufficient representation of this group in clinical trials.
Source link: https://europepmc.org/article/MED/35949112
Pembrolizumab, a programmable death-related immune checkpoint inhibitor, is a type of penetinizumab. Although ICIs have demonstrated effectiveness in lung cancer prevention, they have also been shown to cause a variety of immune-related adverse events. Following receiving carboplatin, nab-paclitaxel, and pemolizumab as fourth-line therapy, we chronicled the case of a 70-year-old man with advanced squamous-cell lung cancer with severe grade 4 hepatitis on day 8. When drug-induced hepatitis caused by anti-cancer therapy, petorizumab is considered, performing a liver biopsy and establishing histological characteristics is required for successful treatment with short-term steroids.
Source link: https://europepmc.org/article/MED/35698605
About 3% of all resected lung cancers are caused by large-cell neuroendocrine carcinomas, which have been categorized as high-grade neuroendocrine carcinomas. LCNECs that contain other components are classified as 'combined LCNECs' and have no specific treatment. Our group was referred to our section by a 73-year-old male with a metastatic brain tumor from a combined LCNEC of the lung containing adenocarcinoma and sarcomatoid components.
Source link: https://europepmc.org/article/MED/35685848
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions